The Role Of Pet Scan In Diagnosis, Staging And Management Of Cancer

Nowadays, PET scans are a crucial part of the diagnostic and staging process for cancer, providing information about the prognosis based on response. This paper aims to provide a thorough analysis of the utility of PET in the locoregional and distant staging of non-small cell lung cancer (NSCLC), as well as to highlight some of the more recent uses and highlight any possible implications for patient care. When evaluating an ambiguous solitary pulmonary nodule or mass, computed tomography (CT) is not as accurate as PET in differentiating between benign and malignant lesions, so PET is the gold standard in this regard. Since PET is far more reliable than CT in assessing the progression of metastases to locoregional lymph nodes, many patients with negative mediastinal PET scans may be spared invasive surgical staging. In cases where invasive surgical staging is required for patients with positive mediastinal PET scans, false-positive results resulting from inflammatory nodes or granulomatous diseases may still exist. PET is a helpful addition to traditional imaging in the hunt for metastatic spread. This could be from the exclusion of malignancy in lesions that are unclear on routine imaging, or it could be the discovery of unanticipated metastatic lesions. PET does not, however, now take the place of traditional imaging. Currently, large-scale randomized trials are being conducted to investigate whether PET staging can genuinely make lung cancer appear better.